{
    "nctId": "NCT00899197",
    "briefTitle": "Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer",
    "officialTitle": "Tamoxifen Resistance in Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Evaluation of the mechanisms of tamoxifen citrate (TAM) resistance in breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer\n\n  * Initial pathologic stage I-IIIB disease\n  * No stage IV disease\n* Meets the following criteria for breast cancer therapy:\n\n  * Received prior primary local therapy for breast cancer\n  * Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks\n* Hormone receptor status:\n\n  * Estrogen-receptor positive tumor\n* Female\n* Pre- or post-menopausal\n* Must be able to donate 20 mL of blood\n\nExclusion Criteria:\n\n* Severe anemia, defined as hemoglobin \\< 11 g/dL\n* Psychiatric history that would preclude obtaining informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}